logo
Share SHARE
FONT-SIZE Plus   Neg

Active Biotech, Ipsen Present OS Data From Tasquinimod Phase II Study In CRPC

Active Biotech (ATVBF.PK) and Ipsen presented overall survival, or OS, data from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer, or CRPC.

The intention-to-treat analysis showed median overall survival times of 33.4 vs. 30.4 months in favor of tasquinimod, longer than previously reported in this metastatic prostate cancer population. A stronger trend for survival benefit is observed in patients with bone metastases. This phase II clinical trial was designed to test the safety and efficacy of tasquinimod.

Noteworthy, 41 patients crossed-over from placebo to tasquinimod. Besides, there were imbalances in baseline prognostic factor in favor of the placebo arm. These were addressed with a multivariate analysis of known CRPC prognostic factors. It showed a statistically significant OS advantage for tasquinimod treated patients with a hazard ratio of 0.64, a decrease of around 40% in the instantaneous risk of event (death), accompanied by improvement in progression-free survival.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Chinese electric vehicle start-up Nio has launched the NIO ES8, a seven-seater electric SUV, at about half the price of Tesla's Model X. The ES8 is Nio's first mass-produced model for the China market. Founded in 2014, Nio unveiled the ES8 in Beijing on Saturday at a base price of 448,000 yuan, or $68,947, before subsidies. This is only about half the price for Tesla's Model X. Bitcoin futures started trading on the world's largest futures exchange, CME Group Sunday, a week after the launch of the very first bitcoin futures on CBOE. CME's own bitcoin futures contract started trading under the ticker "BTC", with the sale price for its January 2018 contracts opening at $20,650. HEICO Corp. (HEI) and Worthington Industries Inc. (WOR) are slated to release their quarterly results on December 18, 2017.
comments powered by Disqus
Follow RTT